“BSGM” Rated Buy by Laidlaw & Co. with $13 Target.

Meeting Reminder…
Join Us for a call with CEO Ken Londoner on Tuesday, 14th April at 17:00 CET/11:00am EST.

BioSig Technologies, Inc. will be hosting a Webinar with Andreea Porcelli, CEO of Swiss Growth ForumTuesday, 14th April at 17:00 CET to discuss its recently acquired anti-viral pharmaceutical candidate, Vicromax(tm).

Please RSVP and find the dial in details HERE.

ViralClear Pharmaceuticals, Inc. will be represented by Nick Spring, CEO, and BioSig will be represented by Kenneth L. Londoner, MBA, Chairman and CEO of BioSig Technologies, Inc.

In a preliminary internal review, the orally administered, broad-spectrum anti-viral agent Vicromax(tm) demonstrated strong activity against COVID-19 in cell cultures in laboratory testing. In this analysis, Vicromax(tm) was added to a tissue culture assay for SARS-CO-2 coronavirus (the causative agent for COVID-19) and an anti-viral effect was observed, which led to a reduction of over 90% of infectious viruses. The Company intends to pursue development of this agent for the treatment of COVID-19 through FDA-approved clinical trials.

The product candidate already completed Phase I and three Phase II clinical trials involving over 134 subjects for indications other than COVID-19, and underwent extensive animal testing and human clinical experience. The Company expects that Vicromax(tm) might be used alone or in a combination with other anti-viral agents or immune modulators.

View the full article on Vicromax(tm) HERE.

View previous SGF BioSig news release here.

Positive Data Generated by BioSig Subsidiary ViralClear on COVID-19 Coronavirus Published in bioRxiv

Westport, CT, April 09, 2020 (GLOBE NEWSWIRE) —

  • Vicromax™ shown to decrease viral production of COVID-19 coronavirus by over 98%
  • Article highlights recent work done in laboratory studies of COVID-19 with Vicromax at the Galveston National Laboratory at The University of Texas Medical Branch

“Oftentimes if an antiviral agent such as Vicromax decreases viral production by over 90% as is presented in this article, it will have meaningful activity in the clinic,” said Dr. Zeldis, ViralClear’s Executive Chair and founder. “More data will be submitted to peer review journals over the coming weeks and we are looking forward to submission of our IND to the FDA and advancing to human trials with this potential therapeutic.”

Vicromax™, a broad-spectrum anti-viral candidate, demonstrated strong activity against COVID-19 in cell cultures in laboratory testing. The pharmaceutical is currently undergoing extensive pre-clinical testing. The Company intends to pursue development of this agent for the treatment of COVID-19 through FDA-approved clinical trials in Q2 2020.

View the full article HERE.

X